Study for AZD4360 in Participants With Advanced Solid Tumours

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.

Trial Details

NCT ID
NCT06921928
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • AZD4360
Locations (sample)
  • Santa Monica, California, United States|34.01949,-118.49138
  • Providence, Rhode Island, United States|41.82399,-71.41283
  • Houston, Texas, United States|29.76328,-95.36327
  • Beijing, China|39.9075,116.39723
  • Chengdu, China|30.66667,104.06667

Key Eligibility Criteria

  • Participant must be ≥ 18 at the time of signing the ICF.
  • Eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
  • Minimum life expectancy of 12 weeks in the opinion of the Investigator.
  • 4 Adequate organ and marrow function, as defined by protocol.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →